Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910966 | 0.80 | DRD2 (0.47) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14220920 | 0.79 | ESR2 (0.39) | CYP19A1SLC18A3ALDH1A1MAPTKMT2A | |
| SCHEMBL29649871 | 0.78 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL522190 | 0.78 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23978388 | 0.78 | SLC18A3 (0.43) | CYP19A1SLC18A3ALDH1A1MAPTKMT2A | |
| SCHEMBL29776876 | 0.78 | MEN1 (0.47) | CYP19A1SLC18A3ALDH1A1MAPTKMT2A | |
| SCHEMBL27793034 | 0.77 | SLC18A3 (0.36) | CYP19A1SLC18A3ALDH1A1GAAGFER | |
| SCHEMBL13569388 | 0.75 | DRD2 (0.46) | CYP19A1ALDH1A1 | |
| SCHEMBL4195824 | 0.75 | DRD2 (0.46) | CYP19A1ALDH1A1 | |
| SCHEMBL25042028 | 0.73 | SLC18A3 (0.34) | CYP19A1SLC18A3ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| EP-4143191-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | iOmx Therapeutics AG (DE) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021219731-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021219731-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | MITF, PRKDC, PRKACA | CYP19A1 1603/4885SLC18A3 4530/4885ALDH1A1 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.